Therefore, Rowe et al introduced a reporting and data system (RADS) for PSMA-PET/CT imaging, termed PSMA-RADS version 1.0, which uses a 5-point scale for the classification of every single lesion and the overall report (PSMA-RADS-1, benign; PSMA-RADS-2, likely benign; PSMA-RADS-3, equivocal; PSMA-RADS-4, prostate cancer highly likely; PSMA-RADS-5, prostate cancer almost certainly) [9, 16]. This evidence concerns the gene FOLH1 and prostate carcinoma.